Home >
News >
#ESHIMMUNE2022 REGISTRATION IS OPEN!
#ESHIMMUNE2022 REGISTRATION IS OPEN!
March 28, 2022
2nd Translational Research Conference
IMMUNE & CELLULAR THERAPIES:
Focus on Advanced Gene-Engineered Immune Cells
September 12-14, 2022
Berlin, Germany
#ESHIMMUNE2022
REGISTRATION IS OPEN!
Looking forward to meeting you face to face in Berlin!
About the Conference:
The
ESH 2nd TRANSLATIONAL RESEARCH E-CONFERENCE: IMMUNE & CELLULAR THERAPIES proposes a programme of leading-edge basic and clinical science, as well as opportunities for informal scientific interaction with a panel of global experts in the field.
It is open to an international audience of biologists and clinicians, including those still in-training. This translational research conference will bring together biologists and clinicians with an interest in immune & cellular therapies with a focus on advanced gene-engineered immune cells.
New data will be presented and spirited debates on how to best to apply these insights to the future of immune & cellular therapies are expected.
Topics:
- Status of pre-clinical and clinical development of CAR-T cell therapy
- Gene editing applied to engineered immune cell therapy
- Engineered immune cell therapy: Beyond T-cells
- Engineered immune cell therapy: Beyond CARs
- Synthetic biology in engineered immune cell therapy
- Engineered immune cell therapy: B-cell tumors and beyond
- Going universal with engineered immune cells
- Overcoming T-cell exhaustion and the immune-suppressive tumor microenvironment
- Imaging engineered immune cells at the receptor, cell and organism level
The programme will include:
• Plenary Sessions
• Panel Discussions
• Simultaneous Meet the Expert Sessions
• Poster Walks
• Brief Oral Communications
For more information, click here!
To meet the faculty, click here!
The programme is already available:
With the support of*:
Premium Conference Partner
*******
Diamond Conference Partner
*******
*ESH conference programmes are developed in strict scientific independence
with no input from corporate sponsors.